PROVIDING FUNDING OPPORTUNITIES FOR INVESTIGATOR-INITIATED TRIALS AND COLLABORATIVE RESEARCH

Investigator Initiated Trial (IIT) refers to an unsolicited study proposal sponsored by a Sponsor-Investigator at a hospital, medical center, medical school, private foundation, private practice, group practice, or government-sponsored research network.

Collaborative Research (CR) is conducted with a non-industry research entity to pursue effective and safe treatments for patients. The Sponsor-Investigator is responsible for leading and executing all aspects of the study. Taiho may provide input, including but is not limited to, methodology, trial design, biostatistical assumptions, pharmacokinetics and translational analyses, study reports, and publication.

By granting opportunities to Sponsor-Investigators, Taiho is committed to advancing research that increases the understanding of scientific and clinical aspects of disease and therapeutics, improving medical care, promoting better healthcare delivery, and providing benefits to patients.

Sponsor-Investigators and/or their affiliated institutions assume responsibility for all aspects of the study including design, regulatory approval, initiation, conduct, oversight, analysis of the results and publication. Sponsor-Investigators are responsible for all study‑related medical decisions, monitoring and adequate medical care for adverse events.

IIT proposals submitted to Taiho are reviewed for scientific merit as well as safety, legal, ethical, and budgetary aspects.

AREAS OF INTEREST:

Trifluridine and Tipiracil
Futibatinib
Decitabine and Cedazuridine
Zipalertinib

APPLY>

Apply for an Investigator Initiated Trial request or view the status of your existing application via our online portal.